Search results
This study found that the overall risk of breast cancer among hormonal contraceptive users is low. Because of the low baseline risks in the age groups using hormonal contraception (ie, premenopausal women), the risk difference between hormonal contraception users and nonusers is small.
7 gru 2017 · The overall absolute increase in breast cancers diagnosed among current and recent users of any hormonal contraceptive was 13 (95% CI, 10 to 16) per 100,000 person-years, or approximately 1...
8 mar 2022 · Levonorgestrel intrauterine sustained release system (LNG-IUS) is an intrauterine hormonal contraceptive device. Breast cancer (BC) was the most common type of cancer in women in the world in 2020. The relationship between LNG-IUS and BC is controversial.
4 lip 2024 · Mirena is a type of intrauterine devices (IUD) that prevents pregnancy for up to 6 years. It works by releasing a hormone called levonorgestrel, a type of progestin. Because of this, Mirena is...
6 dni temu · During follow-up of almost 7 years, hormone-releasing IUD use conferred a 40% higher risk of breast cancer. The data showed a trend toward increasing risk with duration of IUD use, reaching...
Our objective was to conduct a systematic review and meta-analysis of the literature on the risk of breast cancer development in women using the 52-mg levonorgestrel-releasing intrauterine system (LNG-IUS).
18 lis 2020 · A total of 1085 breast cancer cases were found among the 5346 LNG-IUS users, and 4028 cases of breast cancer were found among the 20,219 controls. The results did not give any indication that LNG-IUS use is associated with an increased risk of breast cancer in women younger than 50 years of age.
